Tahoe Therapeutics, the Arc Institute, and Biohub announced a collaborative effort to generate an expansive single‑cell perturbation dataset—over 120 million cells across some 225,000 drug–patient perturbations—to accelerate virtual cell modelling. Each partner committed multimillion‑dollar support and curated perturbations and disease models for public release after an exclusivity window. The dataset will broaden cell‑type coverage, patient‑relevant contexts, and chemical diversity beyond existing resources such as Tahoe‑100M. Tahoe said it will produce roughly four times as many perturbations as its prior dataset, and partners expect the resource to unblock AI models that predict transcriptomic responses to drugs. Who’s involved: Tahoe Therapeutics, Arc Institute, Biohub; announced publicly at JP Morgan and via organizational releases. The dataset aims to be a foundational public asset for virtual cell approaches in drug discovery.